Cilostazol and Endothelial Progenitor Cell

Phase 4 Unknown 60 enrolled Gyeongsang National University Hospital Korea Otsuka Pharmaceutical Co., Ltd. · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

To assess impact of adjunctive cilostazol on endothelial progenitor cell (EPC) mobilization in patients with acute myocardial infarction (To reveal the role of cilostazol in up-regulation of EPC count)

Timeline

Start: 2016-01-01
Primary completion: 2018-12-31
Completion: 2020-07-31

Outcome

Met primary endpoint

paper Cilostazol versus placebo treatment displayed significantly higher changes in EPC levels between baseline and follow-up PMID 32492942 ↗

paper ΔCD133+/KDR+: difference 216%, 95% confidence interval (CI) 44~388%, p = 0.015 PMID 32492942 ↗

Publications

Park Y, Kim JH, Kim TH, Koh JS, Hwang SJ, Hwang JY, Jeong YH. Adjunctive Cilostazol to Dual Antiplatelet Therapy to Enhance Mobilization of Endothelial Progenitor Cell in Patients with Acute Myocardial Infarction: A Randomized, Placebo-Controlled EPISODE Trial. J Clin Med. 2020 Jun 1;9(6):1678. doi: 10.3390/jcm9061678.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cilostazol	Small molecule	200 mg	—
Background	Aspirin	Small molecule	100 mg	—
Background	Clopidogrel	Small molecule	75 mg	—